MED12 mutation is the leading recurrent oncogenic mechanism demonstrated in both benign and malignant breast PTs, but is less frequent in malignant PTs, suggesting that genetic or epigenetic alterations other than MED12 may play a role in tumor aggressiveness and progression. Here, MED12 is linked to neoplasm.